Introduction from Drug peptide supply about PASIREOTIDE/396091-73-9
| English name | PASIREOTIDE |
| Chinese name | 帕瑞肽 |
| CAS NO | 396091-73-9 |
| Peptide sequence | Cyclo[Hyp(2-aminoethylcarboxyl)-Phg-DTrp-Lys-Tyr(Bzl)-Phe] |
| Molecular formula | C58H66N10O9 |
| Molecular weight | 1047.23 |
| storage temperature | 2-8℃ |
| purity | ≥98% |
| Package | 1mg;5mg;10mg;50mg;100mg,1g or according to customer’s detail requirement. |
| Product English synonyms | Cyclo[(2S)-2-phenylglycyl-D-tryptophyl-L-lysyl-O-(phenylmethyl)-L-tyrosyl-L-phenylalanyl-(4R)-4-[[[(2-aminoethyl)amino]carbonyl]oxy]-L-prolyl];SOM320;[(3S,6S,9S,12R,15S,18S,20R)-9-(4-aminobutyl)-3-benzyl-12-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-15-phenyl-6-[(4-phenylmethoxyphenyl)methyl]-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl]N-(2-aminoethyl)carbamate |
Pasireotide overview
Pasireotide bis-aspartate, is a growth hormone inhibitor analog, in the study of growth hormone (GH) releasing factor, in the experiment of distribution in the hypothalamus of mice, a peptide that can inhibit the release of GH was accidentally discovered , this peptide is named somatostatin (SS), which is a 14-amino acid cyclic peptide that acts through the somatostatin receptor on the cell membrane.
Pharmacological effects of pasireotide
There are currently five known somatostatin receptor subtypes in humans: SST1, SST2, SST3, SST4, and SST5. The SST5 subtype is frequently overexpressed in adrenocorticotropic tumor cells from patients with Cushing’s disease, whereas other receptor subtypes are often absent or expressed at low levels. Pasireotide bis-aspartate is a somatostatin analog with a high affinity for SST5, which binds and activates somatostatin receptors to inhibit the secretion of adrenocorticotropic hormone, resulting in decreased secretion of cortisol, thereby relieving illness.
Market prospect of pasireotide
As a somatostatin analog that can bind to multiple receptors, pasireotide is used in the treatment of acromegaly, carcinoid and Cushing’s disease, whether in preclinical tests such as cell experiments, animal experiments, or in clinical In the test, compared with somatostatin analogs such as octreotide and lanreotide, more significant effects were obtained. The results of the phase II trial of pasireotide and the results of one phase III trial have confirmed that pasireotide is a new treatment for new or persistent acromegaly and metastatic carcinoid tumors. may become the first choice for drug treatment.
How to buy pasireotide in the U. S.
Remetide Peptide Supplier specializes in the production and sales of peptides in the USA, as well as professional peptide R&D. Feel free to contact us if you have any questions or inquiries about Peptides.
Hot line:+19498788363
Wechat:americhina
Email:amin@remetide.com